Want to see SYK full AI Analyst Report?

Stryker (SYK) Stock Forecast & Price Target

2,684 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SYK Analyst Ratings

Strong Buy

17 Buy

4 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Stryker

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SYK Stock 12 Month Forecast

Average Price Target

$388.25

▲(13.09% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Stryker in the last 3 months. The average price target is $388.25 with a high forecast of $455.00 and a low forecast of $315.00. The average price target represents a 13.09% change from the last price of $343.32.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"292":"$292","333":"$333","374":"$374","415":"$415","456":"$456"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":455,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$455.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":388.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$388.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":315,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$315.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[292,333,374,415,456],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,313.39,324.2830769230769,335.17615384615385,346.0692307692308,356.96230769230766,367.8553846153846,378.7484615384615,389.64153846153846,400.5346153846154,411.42769230769227,422.3207692307692,433.21384615384613,444.10692307692307,{"y":455,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,313.39,319.1484615384615,324.9069230769231,330.6653846153846,336.42384615384617,342.1823076923077,347.9407692307692,353.6992307692308,359.4576923076923,365.2161538461538,370.9746153846154,376.7330769230769,382.4915384615385,{"y":388.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,313.39,313.51384615384615,313.6376923076923,313.76153846153846,313.8853846153846,314.0092307692308,314.13307692307694,314.25692307692304,314.3807692307692,314.50461538461536,314.6284615384615,314.7523076923077,314.87615384615384,{"y":315,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":392.741,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":373.982,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":387.465,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":361.3,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":353.452,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":369.406,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":349.588,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":366.169,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":384.947,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":328.522,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":293.945,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":298.662,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":313.39,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$455.00

Average Price Target$388.25

Lowest Price Target$315.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Matthew Taylor

Jefferies

$455

Buy

32.53%

Upside

Reiterated

06/18/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Oncolytics Biotech (NASDAQ: ONCY), Stryker (NYSE: SYK) and Alkermes (NASDAQ: ALKS)

Travis Steed

Bank of America Securities

$450→$380

Buy

10.68%

Upside

Reiterated

06/12/26

Stryker price target lowered to $380 from $450 at BofAStryker price target lowered to $380 from $450 at BofA

Joanne Wuensch

Citi

$385

Buy

12.14%

Upside

Reiterated

05/28/26

Citi Sticks to Its Buy Rating for Stryker (SYK)

Richard Newitter

Truist Financial

$380→$330

Hold

-3.88%

Downside

Reiterated

05/04/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Climb Bio (NASDAQ: CLYM), ICU Medical (NASDAQ: ICUI) and Stryker (NYSE: SYK)

Steven Lichtman

William Blair

―

Buy

―

Reiterated

05/01/26

Analysts Conflicted on These Healthcare Names: Moderna (NASDAQ: MRNA) and Stryker (NYSE: SYK)

Jeff Johnson

Robert W. Baird

$437→$385

Buy

12.14%

Upside

Reiterated

05/01/26

Stryker price target lowered to $385 from $437 at BairdStryker price target lowered to $385 from $437 at Baird

Pito Chickering

Deutsche Bank

$402→$315

Hold

-8.25%

Downside

Reiterated

05/01/26

Stryker price target lowered to $315 from $402 at Deutsche BankStryker price target lowered to $315 from $402 at Deutsche Bank

Robbie Marcus

J.P. Morgan

$445→$400

Buy

16.51%

Upside

Reiterated

05/01/26

J.P. Morgan Keeps Their Buy Rating on Stryker (SYK)

Michael Matson

Needham

$454→$418

Buy

21.75%

Upside

Reiterated

05/01/26

Needham Remains a Buy on Stryker (SYK)

Mathew Blackman

TD Cowen

$387→$355

Hold

3.40%

Upside

Reiterated

05/01/26

TD Cowen Keeps Their Hold Rating on Stryker (SYK)

Vijay Kumar

Evercore ISI

$365→$355

Buy

3.40%

Upside

Reiterated

05/01/26

Stryker price target lowered to $355 from $365 at Evercore ISIStryker price target lowered to $355 from $365 at Evercore ISI

Matt Miksic

Barclays

$394

Buy

14.76%

Upside

Reiterated

05/01/26

Analysts Are Bullish on These Healthcare Stocks: BrightSpring Health Services, Inc. (BTSG), Stryker (SYK)

Larry Biegelsen

Wells Fargo

$456→$418

Buy

21.75%

Upside

Reiterated

05/01/26

Analysts Offer Insights on Healthcare Companies: Stryker (NYSE: SYK) and Larimar Therapeutics (NASDAQ: LRMR)

Ryan Zimmerman

BTIG

$397→$379

Buy

10.39%

Upside

Reiterated

05/01/26

BTIG Reaffirms Their Buy Rating on Stryker (SYK)

David Roman

Goldman Sachs

$357→$361

Hold

5.15%

Upside

Reiterated

05/01/26

Stryker price target raised to $361 from $357 at Goldman SachsStryker price target raised to $361 from $357 at Goldman Sachs

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Matthew Taylor

Jefferies

$455

Buy

32.53%

Upside

Reiterated

06/18/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Oncolytics Biotech (NASDAQ: ONCY), Stryker (NYSE: SYK) and Alkermes (NASDAQ: ALKS)

Travis Steed

Bank of America Securities

$450→$380

Buy

10.68%

Upside

Reiterated

06/12/26

Stryker price target lowered to $380 from $450 at BofAStryker price target lowered to $380 from $450 at BofA

Joanne Wuensch

Citi

$385

Buy

12.14%

Upside

Reiterated

05/28/26

Citi Sticks to Its Buy Rating for Stryker (SYK)

Richard Newitter

Truist Financial

$380→$330

Hold

-3.88%

Downside

Reiterated

05/04/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Climb Bio (NASDAQ: CLYM), ICU Medical (NASDAQ: ICUI) and Stryker (NYSE: SYK)

Steven Lichtman

William Blair

―

Buy

―

Reiterated

05/01/26

Analysts Conflicted on These Healthcare Names: Moderna (NASDAQ: MRNA) and Stryker (NYSE: SYK)

Jeff Johnson

Robert W. Baird

$437→$385

Buy

12.14%

Upside

Reiterated

05/01/26

Stryker price target lowered to $385 from $437 at BairdStryker price target lowered to $385 from $437 at Baird

Pito Chickering

Deutsche Bank

$402→$315

Hold

-8.25%

Downside

Reiterated

05/01/26

Stryker price target lowered to $315 from $402 at Deutsche BankStryker price target lowered to $315 from $402 at Deutsche Bank

Robbie Marcus

J.P. Morgan

$445→$400

Buy

16.51%

Upside

Reiterated

05/01/26

J.P. Morgan Keeps Their Buy Rating on Stryker (SYK)

Michael Matson

Needham

$454→$418

Buy

21.75%

Upside

Reiterated

05/01/26

Needham Remains a Buy on Stryker (SYK)

Mathew Blackman

TD Cowen

$387→$355

Hold

3.40%

Upside

Reiterated

05/01/26

TD Cowen Keeps Their Hold Rating on Stryker (SYK)

Vijay Kumar

Evercore ISI

$365→$355

Buy

3.40%

Upside

Reiterated

05/01/26

Stryker price target lowered to $355 from $365 at Evercore ISIStryker price target lowered to $355 from $365 at Evercore ISI

Matt Miksic

Barclays

$394

Buy

14.76%

Upside

Reiterated

05/01/26

Analysts Are Bullish on These Healthcare Stocks: BrightSpring Health Services, Inc. (BTSG), Stryker (SYK)

Larry Biegelsen

Wells Fargo

$456→$418

Buy

21.75%

Upside

Reiterated

05/01/26

Analysts Offer Insights on Healthcare Companies: Stryker (NYSE: SYK) and Larimar Therapeutics (NASDAQ: LRMR)

Ryan Zimmerman

BTIG

$397→$379

Buy

10.39%

Upside

Reiterated

05/01/26

BTIG Reaffirms Their Buy Rating on Stryker (SYK)

David Roman

Goldman Sachs

$357→$361

Hold

5.15%

Upside

Reiterated

05/01/26

Stryker price target raised to $361 from $357 at Goldman SachsStryker price target raised to $361 from $357 at Goldman Sachs

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TRAXFirst Tracks Biotherapeutics Inc

EVMNEvommune, Inc.

MPLTMapLight Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.

AAPGAscentage Pharma Group International Unsponsored ADR

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Stryker

3 Months

Robbie MarcusJ.P. Morgan

Success Rate

14/17 ratings generated profit

Average Return

+4.46%

Copying Robbie Marcus's trades and holding each position for 3 Months would result in 82.35% of your transactions generating a profit, with an average return of +4.46% per trade.

1 Year

Larry BiegelsenWells Fargo

Success Rate

19/25 ratings generated profit

Average Return

+10.60%

Copying Larry Biegelsen's trades and holding each position for 1 Year would result in 76.00% of your transactions generating a profit, with an average return of +10.60% per trade.

2 Years

Robbie MarcusJ.P. Morgan

Success Rate

14/17 ratings generated profit

Average Return

+21.27%

Copying Robbie Marcus's trades and holding each position for 2 Years would result in 82.35% of your transactions generating a profit, with an average return of +21.27% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SYK Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SYK has received 18 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. SYK average Analyst price target in the past 3 months is 388.25.

Each month's total comprises the sum of three months' worth of ratings.

SYK Financial Forecast

SYK Earnings Forecast

Next quarter’s earnings estimate for SYK is $3.49 with a range of $3.36 to $3.61. The previous quarter’s EPS was $2.60. SYK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year SYK has Performed in-line its overall industry.

SYK Sales Forecast

Next quarter’s sales forecast for SYK is $6.58B with a range of $6.52B to $6.80B. The previous quarter’s sales results were $6.02B. SYK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year SYK has Performed in-line its overall industry.

SYK Stock Forecast FAQ

What is SYK’s average 12-month price target, according to analysts?

Based on analyst ratings, Stryker Corp’s 12-month average price target is 388.25.

What is SYK’s upside potential, based on the analysts’ average price target?

Stryker Corp has 13.09% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SYK a Buy, Sell or Hold?

Stryker Corp has a consensus rating of Strong Buy which is based on 17 buy ratings, 4 hold ratings and 0 sell ratings.

What is Stryker Corp’s price target?

The average price target for Stryker Corp is 388.25. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $455.00 ,the lowest forecast is $315.00. The average price target represents 13.09% Increase from the current price of $343.32.

What do analysts say about Stryker Corp?

Stryker Corp’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of SYK?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Stryker (SYK) Stock Forecast & Price Target

SYK Analyst Ratings

SYK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Stryker

SYK Analyst Recommendation Trends

SYK Financial Forecast

SYK Earnings Forecast

SYK Sales Forecast

SYK Stock Forecast FAQ

Detailed List of Analyst Forecasts